We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




MRI/PET Scans Link Brainstem Atrophy to Dementia Symptoms

By MedImaging International staff writers
Posted on 11 Apr 2022
Image: Brainstem atrophy is linked to extrapyramidal symptoms in frontotemporal dementia (Photo courtesy of Unsplash)
Image: Brainstem atrophy is linked to extrapyramidal symptoms in frontotemporal dementia (Photo courtesy of Unsplash)

Frontotemporal dementia, FTD, is an umbrella term for degenerative brain diseases that affect behaviour and cognition. Sometimes, FTD comes with extrapyramidal symptoms, such as those in Parkinson’s disease, and this makes the diagnosis of FTD challenging. However, a new study now shows that accurate imaging and analysis of the brain may make it possible to distinguish between FTD and other diseases that cause extrapyramidal symptoms.

The new study from the University of Eastern Finland (Kuopio, Finland) shows that FTD patients with extrapyramidal symptoms have brainstem atrophy and reduced metabolism in certain areas of the brain significantly more often than patients without extrapyramidal symptoms. This observation can facilitate differential diagnostics in FTD. Extrapyramidal symptoms refer to involuntary movements, typically tremor, slowness, stiffness, loss of facial expressions and automatic movements, such as arm swing when walking. They are often associated with extrapyramidal disorders such as Parkinson’s disease and atypical parkinsonism. Examples of atypical parkinsonism include progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). They share disease mechanisms with FTD, which is why they are nowadays considered to be part of the same spectrum of diseases. FTD is traditionally divided into two main categories: the more common variant with behavioral changes as an early symptom, and the rarer primary progressive aphasia (PPA) with problems related to speech as an early symptom.

Neurodegeneration associated with progressive memory disorders is typically imaged in two ways: magnetic resonance imaging (MRI) of the brain provides accurate information on brain structures and volumes of the different parts of the brain, whereas positron emission tomography, or a PET scan, provides information on metabolism in different areas of the brain. Degeneration of the brain tissue is often preceded by slow or missing metabolism. In the new study, the researchers analyzed medical records on a total of 139 patients with FTD, PSP or CBD, focusing in particular on their diagnosis and the presence of extrapyramidal symptoms. The patients’ MRI and PET images were analyzed using automated analysis software.

The researchers found that patients with extrapyramidal symptoms also had atrophy of the basal ganglia in the midbrain, and of the brainstem. When looking at patients with FTD alone, it was found that patients with extrapyramidal symptoms had brainstem atrophy considerably more often than patients without extrapyramidal symptoms. In addition, PET image analyses showed reduced metabolism in the superior cerebellar peduncle and the frontal lobes in patients with extrapyramidal symptoms. The study showed, for the first time, that significant structural and metabolic differences can be detected in the brain of FTD patients with extrapyramidal symptoms, compared to patients without these symptoms.

“If our findings are confirmed in other cohorts, they can be used in early diagnostics to distinguish between FTD and Parkinson's disease, for example. These findings will also provide us with a better understanding of the mechanisms of these diseases,” said doctoral researcher Sami Heikkinen. “Although the treatment of these diseases is symptomatic at the moment, an early and accurate diagnosis is an important step towards the development of disease modifying treatments.”

Related Links:
University of Eastern Finland 

New
Ultrasound Needle Guidance System
SonoSite L25
New
Post-Processing Imaging System
DynaCAD Prostate
Multi-Use Ultrasound Table
Clinton
3T MRI Scanner
MAGNETOM Cima.X

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.